Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Operating Expenses (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Operating Expenses for 8 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 43.32% to $12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, down 76.17% year-over-year, with the annual reading at -$3.1 million for FY2025, 184.27% down from the prior year.
  • Operating Expenses for Q4 2025 was $12.2 million at Outlook Therapeutics, up from -$29.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $21.6 million in Q4 2024, with the low at -$29.9 million in Q3 2025.